In Phase 2 trial of Tildrakizumab in active PsA efficacy tended to be lower among patients with comorbid MetS, with improvements from baseline across efficacy measures generally larger in patients without MetS vs those with MetS @RheumNow #ACR21 Abst#1819 https://t.co/ATxaFz9X2O https://t.co/2iJMNmfUzg

• Tildrakizumab Efficacy and Safety in Patients with Psoriatic Arthritis by Metab…

Post hoc analysis of pooled data from 19 clin trials on SEC & CV risk & systemic #inflammation in PsO, PsA, AS 📌Traditional CV parameters remained stable on all SEC treated grps 📌SEC sig. ⬇hsCRP & NLR @RheumNow #ACR21 abs1835 https://t.co/iCaGFbXNXn

2 year study shows low rates of radiographic progression in PsA pts on guselkumab #ACR21 @RheumNow Abs#1805 https://t.co/dobg3cEXXG https://t.co/m1P24qPAhy

• https://bit.ly/3ET6Pes

SERENA interim analysis on interruption of secukinumab in AS and PsA 🔹>=16 wks of Rx before interruption of >= 3 mo. 🔹75-80% of pts reinitiated w/o loading phase 🔹AS: BASDAI, PGA stable 🔹PsA: SJC, TJC returned to Rx baseline https://t.co/3G6rVW8TPv #ACR21 Abst#1361 @RheumNow

• Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patien…

Have you heard of pSpA? (Peripheral) pSpA: distinct clinical phenotype w/ intermediate features between pure PsA & pure axSpA but w/ a higher disease burden compared to both diseases, & lower use of b-DMARDs. Abs 1787 #ACR21 #ACRbest #RheumNow @RheumNow https://t.co/Wsysm7A0Y3 https://t.co/rwQ8ukBEDq

• What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden:…

Pregnant pts w/ PsA, but not AxSpA, at increased risk of pre-eclampsia. In RA pregnancies, pre-eclampsia risk increases w/ dz severity prior/during pregnancy. We need to discuss potential risks w/ pts and OB team. Abs 1722 #ACR21 #RheumNow @RheumNow https://t.co/yeQmNAZ1jV https://t.co/cBfeVKQHfr

• Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatme…

The wave of the future? Study details immune profile which discriminates PsA from PsO using phenotyping of serum immune cell subsets & machine learning. Abs 1774 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/huNTY3IdRf https://t.co/3aW64pb9UW

• Blood-based Immune Profiling Combined with Machine Learning Discriminates Psori…

Abst1783 #ACR21 #ACRBest @RheumNow Canadian study reports promising trends on hospitalizations for serious infections in PsA: 2012 – 2017 statist signif ⬇️ in discharges for sepsis, skin & soft tissue infect & UTI (p < 0.001 for all). no statistical difference in the trend of PNA https://t.co/lqtCzUFPAW

Upadacitinib showed similar efficacy in AS pts compared to PsA pts with axial involvement ⭐️PsA pt w/ axial involvement and AS pts with differences in baseline characteristics #ACR21 @RheumNow Abs#1802 https://t.co/QvyayelBYU https://t.co/50dNQm30vf

• https://bit.ly/3bWiQmZ

Excellent overview on assessment of patients with #PsA by @AlexisOgdie! Really clear and easy-to-follow slides to add structure to clinical assessment. #ACR21 @RheumNow https://t.co/XGZrCxOukm

Fr AQUILA study: #Uveitis status in AS or PsA pts given SEC 👁‍🗨3 pts w/o uveitis at BL developed new onset uveitis during study 👁‍🗨Most pts w/uveitis at BL - status remained unchanged or improved 👁‍🗨SEC did not ⬆ risk of uveitis @RheumNow #ACR21 abs1738 https://t.co/IGUpgXBLvt

No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06

Clinical and research pearl: SPACC vs LEEDs enthesitis scoring for your PsA patients by Dr. Ogdie. #ACR21 @RheumNow #RheumNow https://t.co/dDznwSicRQ

Isolated axial involvement exists in 2-5% of PsA patients. In 576 patients 495 (31.4%) had axial disease, of which 32 (2.0%) had isolated axial disease. HLA-B*27+ and lower HAQ scores were associated with isolated axial disease @RheumNow #ACR21 Abst#1775 https://t.co/Y1EAJlA0mT https://t.co/8oZhN3mT30

• Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis - A…

Dr Deike on prevalence and incidence of PsA in Germany. Prevalence 5-6/1000. Incidence 30-40/100000. Marked age variations that don't really make sense for prevalence. Abstr#1785 #ACR21 @RheumNow https://t.co/uW0ruW2Jda